Press Releases
‘Boost for prostate cancer screening – study review shows mortality reduction as high as 31%’
‘Personal ‘risk assessment’ reduces unnecessary biopsies by 33%, confirms latest ERSPC findings’
ROTTERDAM, The Netherlands (8 December 2009)
The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality has been given a boost with new data from the European Randomized Study of Screening for Prostate Cancer (ERSPC). This shows the true impact to be far higher than previously reported – up to 31%. >more
‘PSA Screening Cuts Deaths by 20%, says ERSPC, World’s Largest Prostate Cancer Study’
STOCKHOLM, Sweden (EAU Congress) 18 March 2009
Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published by NEJM, Online First. ERSPC is the world’s largest prostate cancer screening study and provides robust, independently- audited evidence, for the first time, of the effect of screening on prostate cancer mortality. >more
Explanatory Notes
- ERSPC – background
- PSA – the test
- Over diagnosis, Active Surveillance & Prias Project
- Screening Suitability
- Mortality reduction percentage
- Funding
- ‘Risk Based Strategy’ paper in European Urology, Jan 2010
- Copy of full paper on NEJM Online First
For further information:
Jennie Wilde: ERSPC press office, Carver Wilde Communications
t: +44 (0) 20 3178 5563/4 m: +44 (0) 7799 412230 e: jennie@carverwilde.com